$2.03 Billion is the total value of Redmile Group, LLC's 65 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AZN | New | ASTRAZENECA PLCsponsored adr | $76,105,000 | – | 2,246,300 | +100.0% | 3.75% | – |
| AET | New | AETNA INC NEW | $37,182,000 | – | 233,837 | +100.0% | 1.83% | – |
| PRAH | New | PRA HEALTH SCIENCES INC | $30,621,000 | – | 402,014 | +100.0% | 1.51% | – |
| NITE | New | NIGHTSTAR THERAPEUTICS PLCadr | $28,839,000 | – | 1,769,346 | +100.0% | 1.42% | – |
| EPZM | New | EPIZYME INC | $23,051,000 | – | 1,210,000 | +100.0% | 1.14% | – |
| DPLO | New | DIPLOMAT PHARMACY INC | $19,823,000 | – | 957,155 | +100.0% | 0.98% | – |
| CBAY | New | CYMABAY THERAPEUTICS INC | $13,276,000 | – | 1,647,100 | +100.0% | 0.66% | – |
| NLNK | New | NEWLINK GENETICS CORP | $12,712,000 | – | 1,248,700 | +100.0% | 0.63% | – |
| DCPH | New | DECIPHERA PHARMACEUTICALS IN | $11,957,000 | – | 722,880 | +100.0% | 0.59% | – |
| LIFE | New | ATYR PHARMA INC | $9,528,000 | – | 1,886,792 | +100.0% | 0.47% | – |
| TFX | New | TELEFLEX INC | $7,589,000 | – | 31,365 | +100.0% | 0.37% | – |
| PETQ | New | PETIQ INC | $6,682,000 | – | 246,743 | +100.0% | 0.33% | – |
| HOLX | New | HOLOGIC INC | $734,000 | – | 20,000 | +100.0% | 0.04% | – |
| LHCG | New | LHC GROUP INC | $235,000 | – | 3,310 | +100.0% | 0.01% | – |
| SHPG | New | SHIRE PLCsponsored adr | $208,000 | – | 1,360 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 43 | Q3 2023 | 10.1% |
| ATARA BIOTHERAPEUTICS INC | 36 | Q3 2023 | 6.4% |
| FATE THERAPEUTICS INC | 34 | Q3 2023 | 17.2% |
| INVITAE CORP | 32 | Q3 2023 | 2.7% |
| REGENXBIO INC | 28 | Q3 2023 | 3.8% |
| CLOVIS ONCOLOGY INC | 27 | Q1 2020 | 6.7% |
| IMMUNOGEN INC | 27 | Q3 2023 | 13.2% |
| CASTLIGHT HEALTH INC SAN FRAN COM STK | 27 | Q1 2021 | 2.5% |
| ARRAY BIOPHARMA INC | 26 | Q2 2019 | 12.6% |
| DECIPHERA PHARMACEUTICALS IN | 25 | Q3 2023 | 7.0% |
View Redmile Group, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | July 27, 2023 | 2,912,228 | 6.6% |
| IGM Biosciences, Inc. | June 28, 2023 | 3,291,092 | 9.9% |
| MedAvail Holdings, Inc. | June 21, 2023 | 124,507,268 | 73.1% |
| Achilles Therapeutics plc | February 14, 2023 | 1,608,089 | 3.9% |
| Kymera Therapeutics, Inc. | February 14, 2023 | 2,673,837 | 4.9% |
| Old Ayala, IncSold out | February 08, 2023 | 0 | 0.0% |
| Zymeworks Inc. | August 08, 2022 | 5,758,241 | 9.9% |
| Science 37 Holdings, Inc. | June 15, 2022 | 19,808,234 | 17.1% |
| Allakos Inc. | February 14, 2022 | 2,077,875 | 3.8% |
| Aprea Therapeutics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
View Redmile Group, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-03-25 |
| SC 13D/A | 2024-03-25 |
| 4 | 2024-03-19 |
| 4 | 2024-03-14 |
| 4 | 2024-03-13 |
| SC 13D/A | 2024-03-13 |
| 4 | 2024-03-05 |
| SC 13D/A | 2024-03-05 |
View Redmile Group, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.